Petros Pharmaceuticals Inc
petrospharma.comPetros Pharmaceuticals Inc (NASDAQ: PTPI) is a healthcare technology company that is developing a proprietary SaaS and Software as a Medical Device platform designed to assist pharmaceutical companies in switching prescription drugs to over-the-counter products. The company's intended revenue model is technology licensing, out-licensing its platform to pharmaceutical brand owners and OTC commercial licensees rather than generating revenue from drug manufacturing or distribution. Petros was incorporated in Delaware on May 14, 2020, through a merger involving Neurotrope Inc. and Metuchen Pharmaceuticals LLC. Prior to June 2025, the company commercialized Stendra, an FDA-approved PDE-5 inhibitor, through subsidiaries that included Timm Medical Technologies Inc. and Pos-T-Vac LLC. As of the 10-K filed April 15, 2026, the company had divested its historical pharmaceutical commercial operations and the SaaS and SaMD platform remained in early development stages, with no disclosed licensing revenue. The platform is designed around the FDA's Nonprescription Drug Product with an Additional Condition for Nonprescription Use rule.
Products & Services
Proprietary integrated technology platform with two components: (1) a SaaS tool designed to help pharmaceutical companies operationalize Rx-to-OTC switches under the FDA ACNU Rule, and (2) a Software as a Medical Device component intended as a consumer-facing interface for product self-selection. Historically, the company commercialized Stendra (avanafil), an FDA-approved PDE-5 inhibitor prescription medication. As of the 10-K filed April 15, 2026, the platform was in early development stages.
Revenue Model
Technology licensing: the company intends to out-license its proprietary SaaS and SaMD platform to pharmaceutical companies and OTC licensees, with licensees bearing production and supply chain costs. As of the 10-K filed April 15, 2026, the platform was in early development and no licensing revenue was disclosed.
Customers & Markets
Target customers are pharmaceutical brand owners with prescription drug portfolios seeking Rx-to-OTC switches, and exclusive OTC commercial licensees. Secondary targets include self-care consumer companies and health technology companies combining digital platforms with OTC treatment solutions.
Financial Snapshot
Loading...
